OTCMKTS:AGNPF Algernon Pharmaceuticals (AGNPF) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free AGNPF Stock Alerts $0.08 +0.02 (+34.48%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$0.08▼$0.0850-Day Range$0.05▼$0.0852-Week Range$0.04▼$0.26Volume6,748 shsAverage Volume17,090 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Algernon Pharmaceuticals alerts: Email Address Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial Here About Algernon Pharmaceuticals Stock (OTCMKTS:AGNPF)Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia. The company's pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.Read More AGNPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGNPF Stock News HeadlinesMarch 28, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough TreatmentMarch 28, 2024 | americanbankingnews.comAlgernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Short Interest Up 68.2% in MarchMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 27, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - AGNMarch 27, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - AGNMarch 27, 2024 | proactiveinvestors.comAlgernon Pharmaceuticals closes $2M acquisition of its chronic cough research program by SeyltxMarch 27, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity PositionJanuary 31, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKDMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.January 11, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary FibrosisDecember 27, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Increase to Private PlacementNovember 30, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLDNovember 22, 2023 | msn.comSeyltx acquires Algernon's chronic cough research program for $2M and 20% stakeNovember 22, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity PositionNovember 12, 2023 | uk.finance.yahoo.comAlgernon Pharmaceuticals Inc. (AGN.CN)November 8, 2023 | msn.comAlgernon gets Japanese patent notice of allowance for treatment of NASH with RepirinastNovember 8, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with RepirinastSeptember 9, 2023 | investing.comAlgernon Pharmaceuticals Inc Class A (AGN)September 6, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASHAugust 8, 2023 | benzinga.comDMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 StudyAugust 8, 2023 | finance.yahoo.comAlgernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke StudyJuly 14, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory AgreementJune 27, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development ProgramJune 6, 2023 | finance.yahoo.comAlgernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough ConferenceJune 5, 2023 | finance.yahoo.comAlgernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose studyJune 5, 2023 | proactiveinvestors.comAlgernon Pharmaceuticals subsidiary completes DMT escalating dose studyJune 5, 2023 | finance.yahoo.comAlgernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI StudiesSee More Headlines Receive AGNPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Algernon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:AGNPF CUSIPN/A CIK1642178 Webalgernonpharmaceuticals.com Phone604-398-4175FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Christopher J. Moreau (Age 59)CEO & Director Comp: $403.25kMr. James F. Kinley C.A. (Age 46)CPA, Chief Financial Officer Comp: $214.92kDr. Christopher Bryan Ph.D. (Age 41)Vice President of Research & Operations Comp: $222.33kKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors AGNPF Stock Analysis - Frequently Asked Questions How have AGNPF shares performed in 2024? Algernon Pharmaceuticals' stock was trading at $0.0535 on January 1st, 2024. Since then, AGNPF stock has increased by 45.8% and is now trading at $0.0780. View the best growth stocks for 2024 here. Are investors shorting Algernon Pharmaceuticals? Algernon Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 32,300 shares, an increase of 68.2% from the February 29th total of 19,200 shares. Based on an average daily volume of 21,900 shares, the short-interest ratio is currently 1.5 days. View Algernon Pharmaceuticals' Short Interest. When did Algernon Pharmaceuticals' stock split? Algernon Pharmaceuticals shares split before market open on Friday, March 3rd 2023. The 4-1 split was announced on Friday, March 3rd 2023. The newly issued shares were payable to shareholders after the market closes on Friday, March 3rd 2023. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. How do I buy shares of Algernon Pharmaceuticals? Shares of AGNPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:AGNPF) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry ResearchSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Algernon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.